Vertex Pharmaceuticals ($VRTX) has rolled to European approval of its pioneering cystic fibrosis drug Kalydeco as expected, following the early nod for treatment in January from the FDA to treat a subset of patients with the G551D mutation. The Cambridge, MA-based drugmaker expands the market for the treatment with the latest approval, estimating that about 1,100 patients in Europe have the mutation. Kalydeco is the first drug that addresses the underlying cause of the chronic disease rather than the symptoms such as lung infections and dietary issues. Article